Paris - Delayed Quote EUR

TME Pharma N.V. (ALTME.PA)

Compare
0.0758 -0.0002 (-0.26%)
As of 4:33:15 PM GMT+1. Market Open.
Currency in EUR All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
5,624.0000
5,624.0000
11,996.0000
13,451.0000
5,781.0000
Operating Income
-5,624.0000
-5,624.0000
-11,996.0000
-13,451.0000
-5,781.0000
Net Non Operating Interest Income Expense
-1,119.0000
-1,119.0000
-3,097.0000
-1,185.0000
-4,637.0000
Pretax Income
-6,734.0000
-6,734.0000
-15,126.0000
-14,452.0000
-10,406.0000
Tax Provision
2.0000
2.0000
7.0000
1.0000
--
Net Income Common Stockholders
-6,736.0000
-6,736.0000
-15,132.0000
-14,452.0000
-10,405.0000
Diluted NI Available to Com Stockholders
-6,736.0000
-6,736.0000
-15,132.0000
-14,452.0000
-10,405.0000
Basic EPS
-1.34
--
-12.86
-19.85
-29.01
Diluted EPS
-1.34
--
-12.86
-19.85
-29.01
Basic Average Shares
5,018.6040
--
1,176.3670
727.9390
356.9760
Diluted Average Shares
5,018.6040
--
1,176.3670
727.9390
356.9760
Total Operating Income as Reported
-5,615.0000
-5,615.0000
-12,029.0000
-13,267.0000
-5,769.0000
Total Expenses
5,624.0000
5,624.0000
11,996.0000
13,451.0000
5,781.0000
Net Income from Continuing & Discontinued Operation
-6,736.0000
-6,736.0000
-15,132.0000
-14,452.0000
-10,405.0000
Normalized Income
-6,736.0000
-6,736.0000
-15,132.0000
-14,452.0000
-10,405.0000
Interest Income
399.0000
399.0000
303.0000
319.0000
418.0000
Interest Expense
1,518.0000
1,518.0000
3,400.0000
1,504.0000
5,055.0000
Net Interest Income
-1,119.0000
-1,119.0000
-3,097.0000
-1,185.0000
-4,637.0000
EBIT
-5,216.0000
-5,216.0000
-11,726.0000
-12,948.0000
-5,351.0000
EBITDA
-5,072.0000
-5,072.0000
-11,634.0000
-12,882.0000
-5,288.0000
Reconciled Depreciation
144.0000
144.0000
92.0000
66.0000
63.0000
Net Income from Continuing Operation Net Minority Interest
-6,736.0000
-6,736.0000
-15,132.0000
-14,452.0000
-10,405.0000
Normalized EBITDA
-5,072.0000
-5,072.0000
-11,634.0000
-12,882.0000
-5,288.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
--
12/31/2020 - 9/30/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers